TRACON Announces Publication in Clinical Cancer Research of Phase 2 Clinical Data for TRC102, a DNA Damage Repair Inhibitor, in Recurrent Glioblastoma Patients

Stock Information for TRACON Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About TRACON Pharmaceuticals Inc.

TRACON Pharmaceuticals Announces it Will Wind Down Operations
TRACON Pharmaceuticals Announces Termination of ENVASARC Trial and Will Explore Strategic Alternatives Leveraging its In-House Product Development Platform
TRACON Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
TRACON to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024
TRACON Pharmaceuticals Announces Reverse Stock Split
TRACON Pharmaceuticals Provides Update on Ongoing ENVASARC Phase 2 Pivotal Trial Following Independent Data Monitoring Committee Recommendation to Continue the Trial as Planned
TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
TRACON to Report Fourth Quarter and Year-End 2023 Financial Results and Provide Corporate Update on March 5, 2024

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.